Colorectal cancers expressing the mutant BRAFV600E comprise 10% of all metastatic colorectal cancers, present with a poor prognosis, and are refractory to common therapies. We discovered that a subgroup of these tumors that carries loss-of-function RNF43 mutations is associated with significantly improved response to the current standard-of-care anti-BRAF–anti-EGFR combination therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Xi, Y. & Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 14, 101174 (2021). This is a statistics update of global CRC incidence and mortality data.
Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306–1315 (2015). This paper shows the poor prognosis of patients with BRAFV600E CRC.
Corcoran, R. B. et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012). This paper characterizes the positive EGFR feedback loop as a mechanism of resistance in BRAFV600E CRCs.
Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019). This paper reports the results of the phase 3 clinical trial of anti-BRAF–anti-EGFR combination therapy, which became the new standard of care for BRAFV600E CRCs.
Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012). This paper provides mechanistic insights into the function of RNF43 on the Wnt pathway.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Elez, E. et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat. Med. https://doi.org/10.1038/s41591-022-01976-z (2022).
Rights and permissions
About this article
Cite this article
A biomarker of response to therapy in metastatic BRAFV600E colorectal cancers. Nat Med 28, 2015–2016 (2022). https://doi.org/10.1038/s41591-022-01988-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01988-9
